Aclaris Therapeutics (ACRS) reported Q4 Revenue

Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 Revenue for the quarter came in at $9.21 million versus the consensus estimate of $2.08 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• FOMC minutes from July 28-29th meeting